<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00458315</url>
  </required_header>
  <id_info>
    <org_study_id>Cis/Gem/Tax +/- Avastin</org_study_id>
    <nct_id>NCT00458315</nct_id>
  </id_info>
  <brief_title>Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor</brief_title>
  <official_title>Randomized Fase II Trial: Comparing Cisplatin, Paclitaxel and Gemcitabine Versus Cisplatin, Paclitaxel, Gemcitabine and Avastin in Patients With Unknown Primary Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of Cisplatin, Paclitaxel,&#xD;
      Gemcitabine +/- Avastin (Bevacizumab) in patients with unknown primary tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon determination of eligibility, all patients will be randomly assigned to one of two&#xD;
      treatment arms:&#xD;
&#xD;
      Arm A: Cisplatin, Paclitaxel and Gemcitabine&#xD;
&#xD;
        -  Cisplatin 75 mg/m2 IV infusion, Day 1&#xD;
&#xD;
        -  Paclitaxel 175 mg/m2 IV infusion, Day 1&#xD;
&#xD;
        -  Gemcitabine 1000 mg/m2 IV infusion, Day 1 and 8&#xD;
&#xD;
      Arm B: Cisplatin, Paclitaxel, Gemcitabine and Avastin (Bevacizumab)&#xD;
&#xD;
        -  Cisplatin 75 mg/m2 IV infusion, Day 1&#xD;
&#xD;
        -  Paclitaxel 175 mg/m2 IV infusion, Day 1&#xD;
&#xD;
        -  Gemcitabine 1000 mg/m2 IV infusion, Day 1 and 8&#xD;
&#xD;
        -  Bevacizumab 7,5 mg/m2 IV infusion, Day 1&#xD;
&#xD;
      Patients will be stratified by number of metastatic sites (one versus two or more) and the&#xD;
      level of Lactate Dehydrogenase (normal versus high).&#xD;
&#xD;
      The regimens will be repeated every 21 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    never been started&#xD;
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Duration</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Unknown Primary Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin (Bevacizumab)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Unknown primary tumors&#xD;
&#xD;
          2. ECOG performance status 0-1&#xD;
&#xD;
          3. Adequate kidney, liver and bone marrow function&#xD;
&#xD;
          4. No prior chemotherapy&#xD;
&#xD;
          5. Life expectancy &gt; 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The following specific syndromes:&#xD;
&#xD;
               -  Squamous carcinoma limited to cervical glands&#xD;
&#xD;
               -  Women with adenocarcinoma isolated to axillary nodes&#xD;
&#xD;
               -  Women with adenocarcinoma isolated to peritoneal involvements&#xD;
&#xD;
               -  Young men (&lt;55 years) with growing mid-line tumors where a germ cell tumor could&#xD;
                  be expected&#xD;
&#xD;
               -  Neuroendocrine carcinomas&#xD;
&#xD;
          2. Tumor located close to major blood vessels and judged to possess a high risk of&#xD;
             serious bleeding&#xD;
&#xD;
          3. Any significant cardiac disease&#xD;
&#xD;
          4. Clinically significant peripheral vascular disease&#xD;
&#xD;
          5. History of myocardial infarction or stroke within 6 months&#xD;
&#xD;
          6. Evidence of coagulopathy&#xD;
&#xD;
          7. Use of ASA, NSAIDs or clopidogrel&#xD;
&#xD;
          8. Pregnancy or breast feeding&#xD;
&#xD;
          9. Ongoing therapeutic anti-coagulation&#xD;
&#xD;
         10. Hypertension with blood pressure &gt; 150/100 mmHg&#xD;
&#xD;
         11. Brain metastases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gedske Daugaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Dept of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet, Dept of Oncology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>April 6, 2007</study_first_submitted>
  <study_first_submitted_qc>April 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2007</study_first_posted>
  <last_update_submitted>May 6, 2015</last_update_submitted>
  <last_update_submitted_qc>May 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Gedske Daugaard</investigator_full_name>
    <investigator_title>dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

